BGB-283 (lifirafenib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BGB-283 (lifirafenib), covering 2026-01-07 to 2026-01-07. Get the full timeline:
Most recent: Clinical Trial Update: Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors [Phase 1]